Search clinical trials for: MEDI8367

Total 17 results

MedImmune LLC

Completed

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

Healthy Adults

United Kingdom
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

Chronic Kidney Disease

United States
MedImmune LLC

Completed

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants (MEDI8897 1b)

Respiratory Syncytial Virus

United States, South Africa, Chile
AstraZeneca
IQVIA RDS (Shanghai) Co., Ltd.

Completed

Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults (PK/ADA)

Evaluate PK Profile

China
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) (MELODY)

Respiratory Syncytial Virus Infections

United States, Finland, Spain, Belgium, France, Korea, Republic of, Turkey, Austria, New Zealand, South Africa, Australia, Germany, Bulgaria, United Kingdom, Ukraine, Argentina, Czechia, Panama, Estonia, Lithuania, Poland, Japan, Co... and more
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (JUBILUS)

Respiratory Syncytial Virus Infections

Japan
AstraZeneca
Covance; ICON plc; PHT Corporation

Terminated

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (MEDI8897 Ph2b)

Respiratory Syncytial Virus Infections

United States, Canada, Finland, France, Italy, Spain, Belgium, Hungary, Turkey, United Kingdom, New Zealand, Brazil, South Africa, Australia, Bulgaria, Czechia, Poland, Estonia, Lithuania, Chile, Latvia, Sweden, Argentina
AstraZeneca
Iqvia Pty Ltd

Completed

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (MUSIC)

RSV Infection

United States, Belgium, Spain, Japan, Poland, South Africa, United Kingdom, Ukraine
AstraZeneca
IQVIA RDS Inc.

Recruiting

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (CHIMES)

Lower Respiratory Tract Infection

China
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (SPRING)

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Czech Republic, Poland, United Kingdom, Philippines, Latvia, Lithuania, Ukraine, Hungary
AstraZeneca

Completed

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Respiratory Syncytial Virus Infections

United States, France, Italy, Spain, Belgium, Russian Federation, Poland, Turkey, New Zealand, Austria, Korea, Republic of, Germany, Hungary, Bulgaria, Ukraine, South Africa, Japan, Estonia, Lithuania, United Kingdom, Canada, Czechia and more
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
TTY Biopharm

Unknown

Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Taiwan
MedImmune LLC

Completed

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age (MI-CP206)

Healthy or Stable Underlying Chronic Medical Condition

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Advanced Recurrent Ovarian Tumors

United States

Search clinical trials for: MEDI8367

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations